Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Safety assessed by incidence of adverse drug reactions

Adverse drug reactions will be coded using Medical Dictionary for Regulatory Activities (MedDRA).

Time frame: Up to Week 36

Efficacy assessed by Global assessment of relief of IBS and constipation symptoms

Global assessment of relief of IBS and constipation symptoms will be evaluated based on the clinical course in a medical interview with the patient and evaluate efficacy using a 7-point scale: 1: much better; 2: better; 3: a little better; 4: no change; 5: a little worse; 6: worse; 7: much worse. If the evaluation is impossible, a reason will be provided.

Time frame: Up to Week 36